MaltSci 麦伴科研

Appearance

Popular Reports / Emerging Frontiers

This report is written by MaltSci based on the latest literature and research findings

What are the applications of stem cell therapy? ​

Abstract ​

Stem cell therapy has emerged as a revolutionary approach in regenerative medicine, offering innovative solutions for various diseases and injuries previously considered untreatable. The unique properties of stem cells, such as their ability to differentiate into multiple cell types and self-renew, position them as key agents in tissue and organ repair. This report provides a comprehensive overview of the applications of stem cell therapy across several medical fields, including hematology, neurology, cardiology, and orthopedics. In hematology, stem cells have transformed the treatment of conditions like leukemia and lymphoma through hematopoietic stem cell transplantation. In neurology, they hold potential for repairing spinal cord injuries and treating neurodegenerative diseases. In cardiology, advancements in myocardial infarction recovery and heart failure treatment are being explored through stem cell interventions. Additionally, orthopedic applications include cartilage regeneration and bone healing, addressing critical musculoskeletal challenges. Ethical considerations and regulatory challenges remain significant barriers to the widespread adoption of stem cell therapies, particularly regarding the sourcing of embryonic stem cells and the commercialization of unproven treatments. The report emphasizes the importance of establishing robust regulatory frameworks to ensure the safe and effective application of stem cell therapies. Looking forward, the future of stem cell therapy is promising, particularly in personalized medicine and tissue engineering, with ongoing research aimed at harnessing the full potential of stem cells to significantly improve patient outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Stem Cell Types
    • 2.1 Embryonic Stem Cells
    • 2.2 Adult Stem Cells
    • 2.3 Induced Pluripotent Stem Cells
  • 3 Applications in Hematology
    • 3.1 Treatment of Leukemia and Lymphoma
    • 3.2 Bone Marrow Transplantation
  • 4 Applications in Neurology
    • 4.1 Treatment of Neurodegenerative Diseases
    • 4.2 Spinal Cord Injury Repair
  • 5 Applications in Cardiology
    • 5.1 Myocardial Infarction Recovery
    • 5.2 Heart Failure Treatment
  • 6 Applications in Orthopedics
    • 6.1 Cartilage Regeneration
    • 6.2 Bone Healing
  • 7 Ethical Considerations and Regulatory Challenges
    • 7.1 Ethical Issues in Stem Cell Research
    • 7.2 Regulatory Framework and Approval Processes
  • 8 Future Directions and Innovations
    • 8.1 Personalized Medicine Approaches
    • 8.2 Advances in Tissue Engineering
  • 9 Summary

1 Introduction ​

Stem cell therapy has emerged as a revolutionary approach in the field of regenerative medicine, offering promising solutions for a wide array of diseases and injuries that were once deemed untreatable. The unique properties of stem cells, including their ability to differentiate into various cell types and self-renew, position them as powerful agents in the repair and regeneration of damaged tissues and organs. This potential has garnered significant attention from researchers, clinicians, and policymakers alike, prompting a surge in both preclinical and clinical studies aimed at exploring the therapeutic applications of stem cells across multiple medical disciplines.

The significance of stem cell therapy extends beyond mere treatment; it embodies a paradigm shift in how we approach the management of chronic and acute conditions. Conditions such as leukemia, neurodegenerative diseases, heart failure, and orthopedic injuries have been targeted by stem cell interventions, leading to breakthroughs in patient care and outcomes [1][2]. However, despite the enthusiasm surrounding this field, challenges remain. Ethical concerns, particularly regarding the use of embryonic stem cells, alongside regulatory hurdles, continue to pose significant barriers to the widespread adoption of stem cell therapies [3][4].

Currently, the landscape of stem cell therapy is diverse, with various types of stem cells, including embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs), each offering unique advantages and limitations. Embryonic stem cells are celebrated for their pluripotency but are often embroiled in ethical debates. Adult stem cells, on the other hand, are more readily accepted but may have restricted differentiation potential [5][6]. iPSCs, generated through the reprogramming of somatic cells, present a promising alternative, potentially circumventing some ethical issues while retaining the ability to differentiate into any cell type [5][7].

This report aims to provide a comprehensive overview of the applications of stem cell therapy across several key medical fields, including hematology, neurology, cardiology, and orthopedics. In hematology, stem cells have revolutionized the treatment of conditions such as leukemia and lymphoma, primarily through bone marrow transplantation and the use of hematopoietic stem cells [1]. In neurology, stem cell therapy is being explored for its potential to repair spinal cord injuries and treat neurodegenerative diseases [8]. The cardiology sector is witnessing advancements in myocardial infarction recovery and heart failure treatment, leveraging the regenerative capabilities of stem cells [9][10]. Additionally, in orthopedics, stem cells are being utilized for cartilage regeneration and bone healing, addressing critical challenges in musculoskeletal health [11].

Ethical considerations and regulatory challenges are integral to the discourse surrounding stem cell therapy. Issues related to the sourcing of stem cells, particularly from embryos, raise significant moral questions, while the regulatory landscape remains complex and often inconsistent [4]. This report will delve into these ethical dimensions, highlighting the importance of establishing robust regulatory frameworks to ensure the safe and effective application of stem cell therapies [6].

Looking ahead, the future of stem cell therapy is poised for exciting developments, particularly in the realms of personalized medicine and tissue engineering. As research continues to evolve, there is a pressing need for innovative approaches that can harness the full potential of stem cells, ultimately leading to transformative therapies that can significantly improve patient outcomes [12][13].

In summary, this report seeks to inform and educate stakeholders about the multifaceted applications of stem cell therapy, the ongoing challenges, and the future directions of this dynamic field. By synthesizing current literature and clinical trial data, we aim to provide a clear picture of the state of stem cell therapy today and its potential to reshape the landscape of modern medicine.

2 Overview of Stem Cell Types ​

2.1 Embryonic Stem Cells ​

The knowledge base information is insufficient. Please consider switching to a different knowledge base or supplementing relevant literature.

2.2 Adult Stem Cells ​

Stem cell therapy has garnered significant attention in recent years due to its potential applications across a variety of medical fields, particularly in regenerative medicine. Adult stem cells, a critical subset of stem cells, have shown promise in various therapeutic applications. This overview highlights the applications of adult stem cells, focusing on their characteristics, types, and clinical uses.

Adult stem cells, also known as somatic or tissue-specific stem cells, are undifferentiated cells found in various tissues throughout the body. They have the capacity to self-renew and differentiate into specialized cell types, which makes them essential for tissue maintenance and repair. Key types of adult stem cells include hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs), each with distinct properties and applications.

Hematopoietic stem cells (HSCs) are primarily responsible for the formation of blood cells and are widely used in the treatment of hematological disorders, such as leukemia and lymphoma. HSC transplantation is a well-established procedure that can restore the blood and immune system of patients following chemotherapy or radiation therapy. The clinical success of HSCs has paved the way for further research into their applications in regenerative medicine and immune therapies[14].

Mesenchymal stem cells (MSCs), derived from various tissues including bone marrow, adipose tissue, and umbilical cord, have shown significant therapeutic potential in regenerative medicine due to their ability to differentiate into a variety of cell types, including osteoblasts, chondrocytes, and adipocytes. MSCs are also known for their immunomodulatory properties, making them attractive candidates for treating autoimmune diseases and promoting tissue repair in conditions such as osteoarthritis and cardiovascular diseases[15].

The application of MSCs in cardiovascular medicine is particularly noteworthy. MSC therapy has been investigated for its ability to improve cardiac function following myocardial infarction by promoting remuscularization and enhancing vascular repair through paracrine mechanisms. Despite promising preclinical results, the clinical efficacy of MSCs in heart failure remains a topic of ongoing research, with various clinical trials aiming to address the challenges associated with their use, such as cell delivery methods and patient selection[16].

Neural stem cells (NSCs) hold potential for treating neurodegenerative diseases and central nervous system injuries. Research into NSCs has revealed their capacity to differentiate into neurons and glial cells, providing hope for conditions such as amyotrophic lateral sclerosis (ALS) and spinal cord injuries. However, the translation of NSC therapy into clinical practice is hindered by challenges related to the mechanisms of action and the optimal administration routes[17].

Furthermore, the field of stem cell therapy is not without ethical considerations. The phenomenon of "cellular tourism," where patients seek unproven stem cell treatments outside regulated clinical settings, has raised concerns within the scientific community. The importance of adhering to good clinical practice guidelines and ensuring evidence-based methodologies in stem cell research cannot be overstated[18].

In summary, adult stem cells, particularly HSCs, MSCs, and NSCs, represent a diverse array of therapeutic applications in regenerative medicine. While significant progress has been made in understanding their potential, challenges remain in translating these therapies from bench to bedside. Continued research is essential to fully realize the benefits of adult stem cell therapy and to navigate the associated ethical and clinical hurdles.

2.3 Induced Pluripotent Stem Cells ​

Stem cell therapy has emerged as a significant advancement in regenerative medicine, providing innovative approaches for treating a variety of diseases. The applications of stem cell therapy encompass several areas, particularly through the utilization of induced pluripotent stem cells (iPSCs), which are derived from somatic cells and reprogrammed to an embryonic-like pluripotent state. This reprogramming capability allows for the generation of patient-specific stem cells, which can be used in various therapeutic contexts.

One of the most critical applications of stem cell therapy is in the generation of cells and tissues for cell-based therapies. Currently, the availability of donated organs and tissues is limited, necessitating alternative sources for replacement tissues. iPSCs offer a renewable source of differentiated cells that can potentially replace diseased or damaged tissues in conditions such as macular degeneration, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, rheumatoid arthritis, and neurodegenerative diseases [19].

Furthermore, iPSCs have shown great promise in dental research, where they can be developed into disease-specific lines for modeling genetic disorders. This capability enhances the understanding of genetic aberrations and pathogenicity, thereby facilitating drug screening and the development of personalized treatments for orodental disorders [20].

In the realm of central nervous system (CNS) diseases, iPSCs have become invaluable for cellular modeling of various neurological disorders. They provide a platform for studying disease mechanisms, enabling researchers to explore the underlying pathology and potential therapeutic strategies for conditions such as Alzheimer's disease [21]. Recent studies have highlighted the use of iPSC-derived neural models to investigate Alzheimer's disease, focusing on the molecular mechanisms and testing potential drug candidates in vitro [22].

Moreover, the application of iPSCs extends to cancer therapy, where they hold potential for developing novel treatment strategies. Despite the current limitations in demonstrating clinical efficacy, the therapeutic applications of iPSCs for cancer and other diseases continue to be a focal point of research [23].

The technology also facilitates drug discovery and toxicology testing by providing patient-specific models that reflect individual genetic backgrounds. This capability is particularly crucial for personalized medicine, allowing for the development of tailored therapies that consider the unique characteristics of each patient's disease [24].

In summary, the applications of stem cell therapy, particularly through the use of iPSCs, span a wide range of therapeutic areas, including regenerative medicine, disease modeling, drug discovery, and personalized treatments. As research progresses, the potential for iPSCs to revolutionize therapeutic approaches continues to expand, promising significant advancements in treating complex diseases.

3 Applications in Hematology ​

3.1 Treatment of Leukemia and Lymphoma ​

Hematopoietic stem cell transplantation (HCT) has been a cornerstone in the treatment of various hematologic malignancies, including leukemia and lymphoma, for nearly 50 years. The evolution of HCT has paralleled advancements in treatment approaches, particularly with the integration of novel targeted therapies and immunotherapies into standard care protocols. This has prompted a reassessment of HCT's role in the management of these diseases, particularly as new therapies emerge that can alter the timing and objectives of transplantation (Bair et al., 2020) [25].

Cellular immunotherapy is a rapidly advancing field within hematology, aiming to harness the immune system's capabilities to combat malignancies such as leukemia and lymphoma. Recent developments in this area include chimeric antigen receptor (CAR) T-cell therapy, which has shown promise in targeting specific antigens present on the surface of malignant cells. The application of CAR T-cell therapy has demonstrated significant efficacy in treating high-risk patients with acute leukemias and lymphomas, especially those who have not responded to conventional therapies (Cirillo et al., 2018) [26].

Moreover, the use of other cellular therapies, such as mesenchymal stromal/stem cells, has been explored to enhance stem cell engraftment, mitigate graft-versus-host disease (GVHD), and improve overall treatment outcomes in patients undergoing allogeneic HCT. This approach not only provides a therapeutic avenue for patients who are ineligible for traditional transplantation but also offers a less toxic alternative for those with relapsed or refractory disease (Arranz, 2022) [27].

Additionally, non-gene transfer T-cell therapies are being investigated for their potential in targeting non-viral lymphoma- and leukemia-associated antigens, providing a versatile platform for treatment in both autologous settings and post-transplant scenarios. This method allows for the application of T-cell therapies early in the disease process, thereby addressing the needs of the highest-risk patients (Bollard & Barrett, 2014) [28].

In summary, the applications of stem cell therapy in hematology, particularly for leukemia and lymphoma, are expanding through the integration of innovative cellular immunotherapies. These advancements not only enhance the efficacy of treatments but also aim to improve patient outcomes and survival rates in a landscape that is continuously evolving with new therapeutic options.

3.2 Bone Marrow Transplantation ​

Stem cell therapy, particularly through bone marrow transplantation, has evolved significantly over the years, establishing itself as a crucial treatment modality for various hematological and non-hematological diseases. Initially developed as an experimental approach, bone marrow transplantation is now a well-established treatment with defined indications for a wide range of conditions.

One of the primary applications of hematopoietic stem cell transplantation (HSCT) is in the treatment of hematological malignancies, such as leukemia and lymphoma. The procedure involves the infusion of healthy hematopoietic stem cells into patients, which can restore normal blood cell production after high-dose chemotherapy or radiotherapy that is often required to eliminate malignant cells. This approach allows for the administration of high doses of systemic chemotherapy, which confers an antitumor effect beyond that of the chemotherapy alone [29].

In addition to hematological cancers, HSCT is also utilized in the treatment of various non-hematological conditions, including genetic disorders and autoimmune diseases. For instance, autologous HSCT has shown promise as a curative option for severe autoimmune diseases such as multiple sclerosis and scleroderma, where traditional therapies may have limited efficacy [30]. The ability to reset the immune system through HSCT has opened new avenues for treating these challenging conditions [31].

The source of stem cells for transplantation has diversified beyond bone marrow to include peripheral blood stem cells and umbilical cord blood. This expansion has increased the availability of suitable donors, which has more than doubled due to the establishment of large registries of volunteers for marrow donation [32]. The mobilization of stem cells into peripheral blood has been facilitated by hematopoietic growth factors, which play a significant role in the collection and expansion of stem cell pools for transplantation [32].

Furthermore, advances in techniques for histocompatibility typing have enhanced the understanding of graft-versus-host disease (GVHD) and graft-versus-leukemia reactions, leading to improved outcomes for patients undergoing transplantation [32]. The ongoing research into the molecular mechanisms of stem cell homing and migration to the bone marrow is also vital for enhancing the efficacy of HSCT, as successful engraftment is critical for patient prognosis [33].

In summary, stem cell therapy, particularly through bone marrow transplantation, has broad applications in treating hematological malignancies, autoimmune diseases, and genetic disorders. The continual advancements in donor availability, stem cell mobilization techniques, and understanding of transplantation biology promise to further enhance the effectiveness and safety of these therapeutic approaches.

4 Applications in Neurology ​

4.1 Treatment of Neurodegenerative Diseases ​

Stem cell therapy has emerged as a promising approach for treating various neurodegenerative diseases, which are characterized by the progressive loss of neurons in the central nervous system (CNS) and present significant challenges to global health due to their incurable nature. These diseases include multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The regenerative potential of stem cells is harnessed to repair damaged neural tissues and circuits, offering hope for recovery or at least a delay in the progression of symptoms.

Recent advancements in stem cell therapy have demonstrated its potential in various applications within neurology. Stem cells can exert beneficial effects through multiple mechanisms, including direct replacement of lost or damaged neurons, secretion of neurotrophic factors that promote cell survival and growth, and modulation of neuroinflammation [34]. Specifically, different types of stem cells such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) have been investigated for their therapeutic applications in neurodegenerative diseases [35].

In the context of neurodegenerative diseases, stem cell therapy aims to address the significant gaps in current treatment options. For instance, studies have shown that stem cells can improve neurological function in animal models of PD and AD, with some clinical trials reporting positive outcomes [34][36]. The ability of stem cells to release neurotrophic factors not only aids in neuronal survival but also supports the regeneration of neural circuits [37].

Moreover, the combination of stem cell therapy with nanotherapeutic strategies has been highlighted as a promising approach to enhance treatment efficacy. Nanotechnology can facilitate the transport of stem cells, regulate their differentiation, and enable real-time tracking after transplantation, thus addressing some of the limitations associated with traditional stem cell therapies [34].

Despite the potential benefits, challenges remain in the clinical application of stem cell therapies for neurodegenerative diseases. Issues such as poor survival and differentiation rates of transplanted stem cells, insufficient homing ability, and the complexity of tracking these cells post-transplantation need to be addressed [34][35]. Furthermore, ethical considerations and the need for rigorous clinical trials are paramount to ensure the safety and efficacy of these therapies [38].

In summary, stem cell therapy represents a multifaceted approach to treating neurodegenerative diseases, leveraging the regenerative properties of stem cells to repair and restore function in the CNS. As research progresses, it is anticipated that stem cell-based interventions will continue to evolve, potentially leading to more effective treatments for conditions that currently lack adequate therapeutic options [36][37].

4.2 Spinal Cord Injury Repair ​

Stem cell therapy has emerged as a promising avenue for the repair and regeneration of spinal cord injuries (SCI), which pose significant challenges due to their complexity and the irreversible nature of the damage caused. Various studies have investigated the potential applications of stem cell therapy in this context, focusing on different types of stem cells and their mechanisms of action.

Induced pluripotent stem cells (iPSCs) represent a significant advancement in cell therapy for spinal cord injury. These cells can differentiate into various neural cell types, offering the potential to replace damaged neurons and support cells at the injury site. iPSCs have shown promise in preclinical studies, demonstrating their capability to promote recovery and repair after SCI by differentiating into neural precursor cells and facilitating functional recovery [39][40].

Bone marrow stromal cells (BMSCs), a heterogeneous population that includes mesenchymal stem cells, have also been extensively studied for their therapeutic effects in spinal cord repair. BMSCs can migrate to the injury site and release neurotrophic factors that promote cell survival, inhibit apoptosis, and enhance the regeneration of damaged tissues. Research indicates that BMSCs can contribute to functional recovery in animal models of SCI, highlighting their potential for clinical applications [41][42].

Additionally, the paracrine effects of stem cells have gained attention as a mechanism for their therapeutic benefits. It is increasingly recognized that the functional improvements observed after stem cell transplantation may result from the secretion of bioactive molecules rather than direct cell replacement. These factors can stimulate endogenous repair processes, reduce inflammation, and promote tissue restoration [43][44].

Furthermore, adult mesenchymal and neural crest stem cells have shown efficacy in preclinical and clinical settings. Clinical trials have confirmed the beneficial effects of these stem cells, which have been associated with improved functional outcomes in patients with spinal cord injuries. However, a comprehensive understanding of the underlying mechanisms and the precise physiological parameters affected by these cells is still required to optimize their therapeutic protocols [45][46].

In summary, stem cell therapy offers a multifaceted approach to spinal cord injury repair through the differentiation of stem cells into neural cells, the release of neurotrophic factors, and the potential to harness the body’s intrinsic repair mechanisms. Ongoing research aims to refine these strategies, elucidate the mechanisms involved, and enhance the efficacy of stem cell-based therapies for individuals suffering from spinal cord injuries.

5 Applications in Cardiology ​

5.1 Myocardial Infarction Recovery ​

Stem cell therapy has emerged as a promising approach in the field of cardiology, particularly for the recovery following myocardial infarction (MI). The applications of stem cell therapy in this context focus on several key mechanisms and strategies aimed at restoring cardiac function and promoting tissue regeneration.

Following a myocardial infarction, the heart undergoes significant pathological changes, including cardiomyocyte death, hypertrophy, fibroblast activation, extracellular matrix remodeling, and inflammatory response activation. These processes contribute to cardiac remodeling, which ultimately leads to deteriorated heart function. Stem cell therapy aims to address these issues through various mechanisms such as inducing myocardial regeneration, promoting angiogenesis, modulating the inflammatory microenvironment, and reducing fibrosis [47].

Research indicates that stem cells can promote cardiac recovery through multiple pathways. For instance, stem cells are known to secrete paracrine factors that can regulate inflammation, apoptosis, and neovascularization, thereby enhancing the regenerative capacity of the myocardium [48]. Moreover, different types of stem cells, including cardiac stem cells (CSCs), mesenchymal stem cells (MSCs), and hematopoietic stem cells, have shown potential in improving heart function post-MI [[pmid:23238707],[pmid:29642402]].

The delivery methods for stem cell therapy are varied and include intracoronary infusion, direct myocardial injection, and intravenous administration. Each method has its advantages and challenges regarding cell retention and efficacy [49]. Despite the promising nature of these therapies, challenges remain, such as low cell survival rates, excessive fibrosis, and the need for improved clinical translation [47].

Furthermore, recent advancements have focused on preconditioning stem cells with various physical and chemical factors to enhance their survival and efficacy when transplanted. Genetic modifications and the use of bioengineered scaffolds or hydrogels are also being explored to optimize stem cell therapy for myocardial infarction [[pmid:33023264],[pmid:40427036]].

Clinical trials have provided preliminary evidence supporting the safety and feasibility of stem cell therapies for MI recovery. While some studies report modest improvements in left ventricular ejection fraction and clinical status following stem cell transplantation, further randomized controlled trials are necessary to validate these findings and address issues such as optimal timing, cell types, and delivery methods [[pmid:20352151],[pmid:15126257]].

In conclusion, stem cell therapy holds significant promise for myocardial infarction recovery by leveraging the regenerative potential of stem cells to restore cardiac function and mitigate the adverse effects of ischemic injury. Ongoing research is crucial to refine these therapies and translate laboratory findings into effective clinical treatments for patients suffering from myocardial infarction.

5.2 Heart Failure Treatment ​

Stem cell therapy has emerged as a promising approach for the treatment of heart failure, a condition characterized by the heart's inability to pump sufficient blood to meet the body's needs. Heart failure remains a significant global health issue, with approximately 6 million Americans diagnosed and about 40 million adults affected worldwide[50]. The applications of stem cell therapy in cardiology, particularly for heart failure, encompass various strategies aimed at repairing damaged myocardial tissue and improving cardiac function.

One of the primary applications of stem cell therapy in heart failure is the potential to regenerate damaged myocardium. Stem cells possess the unique ability to self-renew and differentiate into various cell types, which can be harnessed to replace or repair myocardial tissue that has been damaged due to myocardial infarction or chronic heart disease[51]. Clinical trials have indicated that stem cell therapy may enhance cardiac function, although the outcomes have been variable, reflecting the complexities involved in patient characteristics, the type of stem cells used, and the method of administration[50][51].

Various types of stem cells have been explored for heart failure treatment, including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), cardiac stem cells (CSCs), and skeletal myoblasts. Each of these stem cell types has distinct properties and potential applications in cardiac repair. For instance, iPSCs can be derived from adult cells and have the capacity to differentiate into cardiac cells, providing a renewable source for therapy[52]. Clinical studies have shown that a combined approach of revascularization and stem cell therapy may yield the most significant benefits, particularly in ischemic cardiomyopathy[50].

However, the effectiveness of stem cell therapy in heart failure has faced challenges. Many clinical trials have reported modest results, with factors such as the low survival rate of transplanted stem cells, the inflammatory environment of the heart, and inadequate blood supply to the transplanted cells potentially hindering therapeutic outcomes[53]. The timing of cell delivery, the route of administration, and the specific patient conditions also play crucial roles in the success of stem cell therapies[54].

In summary, stem cell therapy represents a significant advancement in the treatment of heart failure, offering the potential for myocardial regeneration and improved cardiac function. Despite the current limitations and variability in outcomes, ongoing research and clinical trials continue to refine the application of stem cells in cardiology, with the hope of establishing more effective therapeutic strategies for patients suffering from heart failure[55].

6 Applications in Orthopedics ​

6.1 Cartilage Regeneration ​

Stem cell therapy has emerged as a promising approach in the field of orthopedics, particularly for the regeneration of cartilage. This is particularly relevant in the context of conditions such as osteoarthritis, where traditional surgical interventions often fail to restore the native function and structure of articular cartilage. The application of stem cells in cartilage regeneration encompasses several strategies and mechanisms that are currently under investigation.

Firstly, stem cells are recognized for their potential to differentiate into chondrocytes, the cells responsible for cartilage formation. The regeneration of articular cartilage is critical, as damage to this tissue can lead to significant pain and loss of function in patients. Recent studies indicate that stem cell-mediated cartilage regeneration may occur through both the differentiation of stem cells into chondrocytes and the paracrine effects of stem cell secretomes, which play roles in regulating inflammation and promoting tissue repair [56].

Clinical applications of stem cell therapy for cartilage regeneration include intra-articular injections of stem cells, which have shown promise in alleviating symptoms of knee osteoarthritis and potentially enhancing cartilage repair [57]. This approach involves harvesting stem cells, preparing them, and injecting them directly into the joint space, where they can exert their regenerative effects. Research has indicated that these injections may lead to improvements in pain and inflammation, thereby reducing the need for more invasive procedures such as knee surgery [57].

Moreover, stem cell therapy is being explored in conjunction with advanced biomaterials and scaffolding techniques to enhance the effectiveness of cartilage repair. The combination of stem cells with hydrogels and other scaffold materials aims to create an optimal environment for cell survival, retention, and differentiation [58]. These materials can provide structural support and biochemical cues necessary for the successful regeneration of cartilage tissue.

Despite the potential of stem cell therapy, challenges remain in its clinical application. Variability in the sources of stem cells, methods of cell culture, and delivery techniques can lead to inconsistent outcomes [59]. Additionally, while early clinical results are promising, there is a need for high-quality evidence from randomized clinical trials to fully establish the efficacy and safety of these therapies [60].

Overall, stem cell therapy represents a transformative approach in orthopedic medicine, particularly for cartilage regeneration. It holds the potential to address the limitations of current treatment options and improve the quality of life for patients suffering from degenerative joint diseases. Ongoing research and collaboration among clinicians, researchers, and regulatory bodies are essential to advance this field and translate scientific discoveries into effective clinical applications [61].

6.2 Bone Healing ​

Stem cell therapy has emerged as a promising avenue in orthopedic medicine, particularly for bone healing and regeneration. Various studies highlight the significant role of stem cells in treating orthopedic conditions characterized by impaired healing, such as nonunions, large bone defects, and avascular necrosis.

Stem cells, particularly mesenchymal stem cells (MSCs), are central to bone homeostasis and repair. They serve as progenitor cells from which bone cells are formed and help regulate the local cytokine environment, promoting osteogenesis (Rodham et al., 2024). The therapeutic potential of stem cells is especially relevant in cases of nonunions and fractures, where traditional healing processes fail. Recent progress indicates that stem cell-based strategies can augment fracture repair through various methodologies, including the application of different stem cell sources and enhancement techniques such as genetic modifications (Tseng et al., 2008).

The application of stem cells in orthopedic regenerative medicine encompasses several areas. These include:

  1. Bone Regeneration: Stem cells can be utilized to repair large bone defects, nonunions, and osteonecrosis. Clinical applications of stem cells have shown promise in these areas, although the success rates can vary based on patient profiles and disease characteristics (Li et al., 2015; Im, 2017). The heterogeneity of MSCs and the lack of unique surface antigens complicate the enrichment and application of these cells, necessitating a deeper understanding of their biological properties (Cenni et al., 2010).

  2. Cartilage Repair: Stem cell therapy is also being explored for cartilage regeneration, targeting conditions such as osteoarthritis and focal osteochondral defects. The regenerative capacity of stem cells in cartilage repair is a significant focus, although the current literature primarily consists of case reports and early clinical trials (Mazzoni et al., 2023).

  3. Tendon Regeneration: Research indicates that stem cells may play a crucial role in tendon healing, particularly for conditions affecting the bone-tendon junction, such as rotator cuff tears. However, clinical evidence in this area remains limited compared to bone and cartilage applications (Im, 2017).

  4. Innovative Scaffolds: The integration of stem cells with biomimetic scaffolds has been a focus of recent studies, aiming to enhance bone repair and regeneration. These scaffolds serve as supportive structures that can deliver stem cells and bioactive substances to the injury site, improving the overall therapeutic outcome (Mazzoni et al., 2023).

  5. Endogenous Regeneration: Human amniotic mesenchymal stem cells (hAMSCs) have shown potential in promoting endogenous bone regeneration. Their superior paracrine functions contribute to immune regulation, anti-inflammation, and tissue regeneration, making them a valuable candidate for clinical applications in bone healing (Li et al., 2020).

Despite the encouraging findings, the clinical application of stem cell therapies in orthopedics still faces challenges, including the need for high-quality randomized trials to validate efficacy and safety. As the field evolves, ongoing research will likely refine these applications, enhancing the role of stem cells in orthopedic practice and improving patient outcomes in bone healing (Brown et al., 2024).

7 Ethical Considerations and Regulatory Challenges ​

7.1 Ethical Issues in Stem Cell Research ​

Stem cell therapy has emerged as a promising avenue in regenerative medicine, with applications spanning various medical fields. Researchers are leveraging stem cell technologies in chest medicine for drug discovery, testing therapies for conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis, and producing functional lung and tracheal tissues for potential transplantation. The anticipated clinical impact of stem cell-based regenerative medicine in chest medicine is significant, although it is accompanied by ethical and regulatory challenges [18].

The therapeutic potential of stem cell-based therapies extends to the treatment of degenerative, autoimmune, and genetic disorders. However, their clinical application raises numerous ethical and safety concerns. Ethical dilemmas are particularly pronounced in human embryonic stem cell (hESC) research, where the destruction of embryos poses significant moral questions. Although the advent of induced pluripotent stem cells (iPSCs) has alleviated some of these concerns, issues related to their clinical translation persist, including risks associated with unlimited differentiation potential and the potential for generating genetically engineered embryos [62].

Furthermore, the clinical use of mesenchymal stem cells (MSCs) has shown benefits in treating autoimmune and chronic inflammatory diseases. Nonetheless, there are apprehensions regarding their ability to promote tumor growth and metastasis, which underscores the need for cautious evaluation of their therapeutic potential [62].

The ethical landscape surrounding stem cell therapy encompasses a range of issues, including informed consent, the right to unproven treatments, equitable access to therapies, and the implications for donors. Regulatory frameworks are essential to ensure the responsible translation of stem cell-based therapies into clinical practice. A well-regulated system is necessary to safeguard against the commercialization of unproven therapies and to protect patient safety [63].

Challenges also arise from the commercialization of stem cell treatments, which often occur without adequate scientific validation. This unregulated market can lead to exploitation of patients and misinformation about the efficacy and safety of such interventions [64]. The integration of ethical considerations into clinical practice is crucial for addressing these challenges and ensuring that stem cell therapies are developed and implemented responsibly [65].

In conclusion, while stem cell therapy holds great promise for treating a variety of medical conditions, the ethical and regulatory challenges it presents must be carefully navigated. Addressing these concerns through robust ethical guidelines, regulatory oversight, and ongoing dialogue among stakeholders is vital for the advancement of stem cell research and its applications in clinical settings [66][67][68].

7.2 Regulatory Framework and Approval Processes ​

Stem cell therapy has emerged as a promising avenue in regenerative medicine, offering potential applications across various medical fields. The applications of stem cell therapy include, but are not limited to, the treatment of degenerative diseases, autoimmune disorders, and injuries. Specifically, stem cells are being utilized as models for drug discovery, testing stem cell-based therapies for conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis, and producing functional lung and tracheal tissues for physiological modeling and potential transplantation (Lowenthal & Sugarman, 2015) [18].

Despite the therapeutic potential, the clinical application of stem cell therapies is fraught with ethical and regulatory challenges. Ethical concerns primarily revolve around the source of stem cells, particularly human embryonic stem cells (hESCs), where the destruction of embryos raises significant moral dilemmas. Although induced pluripotent stem cells (iPSCs) have alleviated some of these concerns, ethical questions regarding their use, particularly regarding the risks of tumor formation and the potential for creating genetically engineered embryos, persist (Volarevic et al., 2018) [62]. Furthermore, the use of mesenchymal stem cells (MSCs) has been associated with both beneficial therapeutic effects and the potential for adverse outcomes, such as tumor promotion, which raises safety concerns (Volarevic et al., 2018) [62].

The regulatory landscape for stem cell therapies is complex and varies significantly across countries. There is a pressing need for a well-defined regulatory framework to ensure the safety and efficacy of stem cell-based interventions. Currently, many stem cell therapies are marketed without sufficient evidence of their efficacy, leading to concerns about patient safety and the potential for exploitation by unregulated clinics (Piuzzi et al., 2020) [63]. This unregulated commercialization poses a challenge for legitimate scientific research and patient protection, highlighting the necessity for rigorous regulatory oversight (Sipp, 2011) [64].

To address these challenges, it is essential to establish a comprehensive regulatory framework that governs the development and application of stem cell therapies. Such a framework should incorporate ethical considerations, ensuring informed consent, equitable access to therapies, and the responsible translation of research into clinical practice (Marei, 2025) [65]. Additionally, collaborative efforts among regulators, scientists, clinicians, and patient advocacy groups are crucial to articulate clear expectations and guidelines for the development and delivery of stem cell therapies (Sugarman et al., 2018) [69].

In summary, while stem cell therapy holds great promise for treating various medical conditions, it is imperative to navigate the associated ethical considerations and regulatory challenges effectively. Establishing a robust regulatory framework that addresses these issues will be vital in ensuring the safe and equitable application of stem cell therapies in clinical practice.

8 Future Directions and Innovations ​

8.1 Personalized Medicine Approaches ​

Stem cell therapy represents a significant advancement in personalized medicine, offering tailored treatment strategies for various diseases. The applications of stem cell therapy are diverse and continue to evolve, particularly in the context of personalized medicine. This therapeutic approach leverages the unique properties of stem cells, such as self-renewal and differentiation capabilities, to address a range of medical conditions.

One of the primary applications of stem cell therapy is in regenerative medicine, where stem cells are utilized to repair or replace damaged tissues. For instance, mesenchymal stem cells (MSCs) have been employed for tissue regeneration, with applications in conditions such as spinal cord injury, diabetes, and cardiac disorders [70]. These cells can differentiate into various cell types, including osteoblasts, chondrocytes, and myocytes, making them versatile in treating diverse pathologies [70].

In the realm of cancer treatment, stem cell therapy has shown promise through targeted approaches. Personalized cancer therapies, which take into account the unique genetic and epigenetic features of a patient's tumor, are increasingly being developed. This includes the use of cancer stem cells for targeted therapies and diagnostics, allowing for more effective treatment strategies tailored to individual patient profiles [71]. Additionally, stem cells can be utilized in combination with gene-editing technologies, such as CRISPR-Cas, to create personalized therapies that specifically target cancerous cells [71].

Moreover, stem cells are instrumental in developing patient-specific in vitro models that facilitate drug discovery and testing. These models enable researchers to evaluate the efficacy and safety of new therapeutics in a controlled environment that closely mimics the patient's own biology [72]. The ability to create disease-specific models using induced pluripotent stem cells (iPSCs) allows for the exploration of personalized treatment options based on the individual's genetic makeup [72].

Biomaterials also play a crucial role in enhancing the efficacy of stem cell therapies. By serving as carriers that provide structural support and promote cell viability, biomaterials can help tailor the therapeutic impact of cell therapies to the specific needs of each patient [73]. This personalization can be achieved through the engineering of biomaterials that respond to the unique biological signals present in a patient's tissue environment.

Furthermore, the integration of biological therapies, such as cell and gene therapies, into personalized medicine frameworks underscores the potential for customized treatment regimens [74]. This includes the development of therapeutic vaccines derived from a patient's own tumor cells and adoptive cell therapies that enhance the immune response against cancer [74].

In summary, the applications of stem cell therapy in personalized medicine are extensive and multifaceted. They encompass regenerative medicine, cancer treatment, drug discovery, and the development of innovative biomaterials. The future of stem cell therapy lies in its ability to be precisely tailored to individual patient needs, enhancing treatment efficacy and minimizing adverse effects. As research progresses, the potential for personalized approaches in stem cell therapy will continue to expand, paving the way for more effective and individualized medical interventions.

8.2 Advances in Tissue Engineering ​

Stem cell therapy has garnered significant attention for its potential applications in various fields, particularly in tissue engineering and regenerative medicine. The applications of stem cell therapy are diverse, addressing numerous health issues and injuries, which can be broadly categorized into several key areas:

  1. Tissue Regeneration and Repair: Stem cells are integral to the regeneration of damaged tissues. They possess the ability to differentiate into various cell types, which allows them to contribute to the repair of tissues such as skin, muscle, and nerve. For instance, adult stem cells have shown promise in treating injuries related to the skin, sensory organs, nervous system, musculoskeletal system, and circulatory/pulmonary tissues. This is particularly relevant in military medicine, where stem cells can help manage injuries sustained in combat, thereby saving lives that might have been lost in previous conflicts (Ude et al. 2018) [75].

  2. Skin Tissue Engineering: Stem cell therapy has been extensively utilized in skin tissue engineering, particularly for wound healing. Recent advancements highlight the synergistic effect of combining stem cells with biomaterials, which enhance the survival and therapeutic effects of transplanted cells. This approach not only improves wound healing outcomes but also addresses challenges such as low cell survival rates in injured areas (Riha et al. 2021) [76].

  3. Muscle Tissue Engineering: In the context of skeletal and smooth muscle tissue engineering, adult stem cells are being investigated for their potential to rejuvenate and repair damaged muscle tissues. Research indicates that these cells can effectively contribute to muscle regeneration in patients with muscular diseases or injuries, offering hope for those affected by conditions such as muscular dystrophies (Salemi et al. 2022) [77].

  4. Bone Tissue Engineering: Stem cell therapies are also being applied in bone tissue engineering. Advances in the development of engineered hydrogels and scaffolds are aimed at enhancing the regulation of stem cell fate, which is crucial for successful bone regeneration. These innovations aim to create an optimal microenvironment that supports stem cell differentiation and integration into existing tissues (Liu et al. 2022) [78].

  5. Reproductive Tissue Engineering: The principles of stem cell therapy are being explored in the engineering of reproductive tissues and organs. This area aims to address serious injuries and failures in reproductive organ function, with ongoing research focusing on cell transplantation and bioengineering techniques to restore normal functions in these tissues (Atala 2012) [79].

  6. Neurological Applications: Stem cells are being studied for their potential to repair nerve tissues and support recovery from neurological injuries. The ability of stem cells to modulate immune responses and promote healing in the nervous system represents a significant area of research, with the goal of improving outcomes for conditions like spinal cord injuries (Edalat et al. 2012) [80].

  7. Cancer and Tumor Microenvironment: There is ongoing research into the interactions between stem cells and cancer cells, particularly in the context of cancer recurrence and metastasis. Understanding these dynamics is crucial for developing safer and more effective post-oncological reconstruction strategies (Maj et al. 2018) [81].

  8. Extracellular Matrix (ECM) Interaction: Recent studies emphasize the importance of ECM remodeling in regulating stem cell function. Innovations in how stem cells interact with their microenvironment could lead to enhanced therapeutic efficacy and better outcomes in tissue engineering applications (Xie et al. 2022) [82].

In summary, the applications of stem cell therapy in tissue engineering are vast and varied, encompassing skin, muscle, bone, and neurological tissues, as well as reproductive organs. As research continues to advance, these therapies hold the potential to revolutionize treatment approaches for a wide range of injuries and diseases, paving the way for innovative regenerative strategies in clinical practice.

9 Conclusion ​

Stem cell therapy represents a groundbreaking advancement in regenerative medicine, with diverse applications spanning hematology, neurology, cardiology, and orthopedics. Key findings indicate that hematopoietic stem cells (HSCs) are integral in treating hematological malignancies, while mesenchymal stem cells (MSCs) show promise in regenerative applications across various medical fields. Induced pluripotent stem cells (iPSCs) offer a unique opportunity for personalized medicine, enabling the development of patient-specific therapies. Despite the significant progress made, challenges remain, particularly concerning ethical considerations and regulatory frameworks that govern stem cell research and application. The current landscape reveals a dynamic interplay between scientific innovation and ethical discourse, underscoring the need for continued research and robust regulatory oversight to navigate the complexities of stem cell therapy. Future directions should focus on personalized medicine approaches and advancements in tissue engineering, aiming to enhance the efficacy and safety of stem cell applications while ensuring equitable access to these transformative therapies.

References ​

  • [1] Siti A M Imran;M Haikal Aiman M Hamizul;Ahmad Amin Noordin Khairul Bariah;Wan Safwani Wan Kamarul Zaman;Fazlina Nordin. Regenerative Medicine Therapy in Malaysia: An Update.. Frontiers in bioengineering and biotechnology(IF=4.8). 2022. PMID:35557868. DOI: 10.3389/fbioe.2022.789644.
  • [2] Banu Ismail Mendi;Rahim Hirani;Alyssa Sayegh;Mariah Hassan;Lauren Fleshner;Banu Farabi;Mehmet Fatih Atak;Bijan Safai. Utilization of Stem Cells in Medicine: A Narrative Review.. International journal of molecular sciences(IF=4.9). 2025. PMID:41096924. DOI: 10.3390/ijms26199659.
  • [3] Györgyi Műzes;Ferenc Sipos. Issues and opportunities of stem cell therapy in autoimmune diseases.. World journal of stem cells(IF=3.6). 2019. PMID:31110602. DOI: 10.4252/wjsc.v11.i4.212.
  • [4] William H Fang;C Thomas Vangsness. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association(IF=5.4). 2020. PMID:32442713. DOI: 10.1016/j.arthro.2020.05.015.
  • [5] Liz Simon;Rex A Hess;Paul S Cooke. Spermatogonial stem cells, in vivo transdifferentiation and human regenerative medicine.. Expert opinion on biological therapy(IF=4.0). 2010. PMID:20146635. DOI: 10.1517/14712591003614731.
  • [6] Aleksandra Musiał-Wysocka;Marta Kot;Marcin Majka. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies.. Cell transplantation(IF=3.2). 2019. PMID:31018669. DOI: 10.1177/0963689719837897.
  • [7] Evangelos Kiskinis;Kevin Eggan. Progress toward the clinical application of patient-specific pluripotent stem cells.. The Journal of clinical investigation(IF=13.6). 2010. PMID:20051636. DOI: .
  • [8] L Cacciottola;F Vitale;J Donnez;M M Dolmans. Use of mesenchymal stem cells to enhance or restore fertility potential: a systematic review of available experimental strategies.. Human reproduction open(IF=11.1). 2023. PMID:37954935. DOI: 10.1093/hropen/hoad040.
  • [9] Pablo Díez Villanueva;Ricardo Sanz-Ruiz;Alberto Núñez García;María Eugenia Fernández Santos;Pedro L Sánchez;Francisco Fernández-Avilés. Functional multipotency of stem cells: what do we need from them in the heart?. Stem cells international(IF=3.3). 2012. PMID:22966237. DOI: 10.1155/2012/817364.
  • [10] Martin Klein;Mária Csöbönyeiová;Stanislav Žiaran;Ľuboš Danišovič;Ivan Varga. Cardiac Telocytes 16 Years on-What Have We Learned So Far, and How Close Are We to Routine Application of the Knowledge in Cardiovascular Regenerative Medicine?. International journal of molecular sciences(IF=4.9). 2021. PMID:34681601. DOI: 10.3390/ijms222010942.
  • [11] Reza Tabatabaei Qomi;Mohsen Sheykhhasan. Adipose-derived stromal cell in regenerative medicine: A review.. World journal of stem cells(IF=3.6). 2017. PMID:28928907. DOI: 10.4252/wjsc.v9.i8.107.
  • [12] Chikako Nito;Satoshi Suda;Yuko Nitahara-Kasahara;Takashi Okada;Kazumi Kimura. Dental-Pulp Stem Cells as a Therapeutic Strategy for Ischemic Stroke.. Biomedicines(IF=3.9). 2022. PMID:35453487. DOI: 10.3390/biomedicines10040737.
  • [13] Carmen Bertoni. Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells.. Frontiers in physiology(IF=3.4). 2014. PMID:24795643. DOI: 10.3389/fphys.2014.00148.
  • [14] Shrinivas Acharya;Suyog Shaha;Michael Griffith Bibbey;Malini Mukherji;Zongmin Zhao;Samir Mitragotri. Stem cell therapies in the clinic.. Bioengineering & translational medicine(IF=5.7). 2025. PMID:40385529. DOI: 10.1002/btm2.70000.
  • [15] Quanchi Guo;Yang Hua. Stem Cell Therapy in Ischemic Heart Failure.. American journal of cardiovascular drugs : drugs, devices, and other interventions(IF=3.0). 2025. PMID:40576736. DOI: 10.1007/s40256-025-00741-0.
  • [16] Monisha N Banerjee;Roberto Bolli;Joshua M Hare. Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions.. Circulation research(IF=16.2). 2018. PMID:29976692. DOI: 10.1161/CIRCRESAHA.118.311217.
  • [17] L Galán;A Guerrero-Sola;U Gómez-Pinedo;J Matias-Guiu. [Cell therapy in amyotrophic lateral sclerosis: science and controversy].. Neurologia (Barcelona, Spain)(IF=3.1). 2010. PMID:20964996. DOI: .
  • [18] Justin Lowenthal;Jeremy Sugarman. Ethics and policy issues for stem cell research and pulmonary medicine.. Chest(IF=8.6). 2015. PMID:25732448. DOI: 10.1378/chest.14-1696.
  • [19] Marcie A Glicksman. Induced Pluripotent Stem Cells: The Most Versatile Source for Stem Cell Therapy.. Clinical therapeutics(IF=3.6). 2018. PMID:30049501. DOI: 10.1016/j.clinthera.2018.06.004.
  • [20] Thekkeparambil Chandrabose Srijaya;Padmaja Jayaprasad Pradeep;Rosnah Binti Zain;Sabri Musa;Noor Hayaty Abu Kasim;Vijayendran Govindasamy. The promise of human induced pluripotent stem cells in dental research.. Stem cells international(IF=3.3). 2012. PMID:22654919. DOI: 10.1155/2012/423868.
  • [21] Paige E Cundiff;Stewart A Anderson. Impact of induced pluripotent stem cells on the study of central nervous system disease.. Current opinion in genetics & development(IF=3.6). 2011. PMID:21277194. DOI: 10.1016/j.gde.2011.01.008.
  • [22] Martin Barak;Veronika Fedorova;Veronika Pospisilova;Jan Raska;Simona Vochyanova;Jiri Sedmik;Hana Hribkova;Hana Klimova;Tereza Vanova;Dasa Bohaciakova. Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids.. Stem cell reviews and reports(IF=4.2). 2022. PMID:35107767. DOI: 10.1007/s12015-021-10254-3.
  • [23] Saul J Sharkis;Richard J Jones;Curt Civin;Yoon-Young Jang. Pluripotent stem cell-based cancer therapy: promise and challenges.. Science translational medicine(IF=14.6). 2012. PMID:22461639. DOI: 10.1126/scitranslmed.3003920.
  • [24] Naoki Nagata;Shinya Yamanaka. Perspectives for induced pluripotent stem cell technology: new insights into human physiology involved in somatic mosaicism.. Circulation research(IF=16.2). 2014. PMID:24481841. DOI: 10.1161/CIRCRESAHA.114.303043.
  • [25] Steven M Bair;Joshua D Brandstadter;Emily C Ayers;Edward A Stadtmauer. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy.. Cancer(IF=5.1). 2020. PMID:32073653. DOI: 10.1002/cncr.32659.
  • [26] Melita Cirillo;Peter Tan;Marian Sturm;Catherine Cole. Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation(IF=4.3). 2018. PMID:29102721. DOI: 10.1016/j.bbmt.2017.10.035.
  • [27] Lorena Arranz. The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies.. Cancers(IF=4.4). 2022. PMID:35158848. DOI: 10.3390/cancers14030580.
  • [28] Catherine M Bollard;A John Barrett. Cytotoxic T lymphocytes for leukemia and lymphoma.. Hematology. American Society of Hematology. Education Program(IF=3.2). 2014. PMID:25696912. DOI: 10.1182/asheducation-2014.1.565.
  • [29] F R Appelbaum. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer.. CA: a cancer journal for clinicians(IF=232.4). 1996. PMID:8646545. DOI: 10.3322/canjclin.46.3.142.
  • [30] Francesco Dazzi;Jacob M van Laar;Andrew Cope;Alan Tyndall. Cell therapy for autoimmune diseases.. Arthritis research & therapy(IF=4.6). 2007. PMID:17367542. DOI: 10.1186/ar2128.
  • [31] E D Thomas. Bone marrow transplantation: a review.. Seminars in hematology(IF=4.1). 1999. PMID:10595758. DOI: .
  • [32] H J Kolb;E Holler. Hematopoietic transplantation: state of the art.. Stem cells (Dayton, Ohio)(IF=3.6). 1997. PMID:9368335. DOI: 10.1002/stem.5530150819.
  • [33] Aysegul Ocal Sahin;Miranda Buitenhuis. Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells.. Cell adhesion & migration(IF=3.5). 2012. PMID:22647939. DOI: 10.4161/cam.18975.
  • [34] Min Wei;Zhaofei Yang;Song Li;Weidong Le. Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach.. International journal of nanomedicine(IF=6.5). 2023. PMID:36760756. DOI: 10.2147/IJN.S395010.
  • [35] Md Zamshed Alam Begh;Mehrukh Zehravi;Md Abdul Kuddus Bhuiyan;M Raju Molla;Kannan Raman;Talha Bin Emran;Md Habib Ullah;Irfan Ahmad;Hamid Osman;Mayeen Uddin Khandaker. Recent advances in stem cell approaches to neurodegeneration: A comprehensive review with mechanistic insight.. Pathology, research and practice(IF=3.2). 2025. PMID:40381433. DOI: 10.1016/j.prp.2025.156013.
  • [36] Mingchao Shi;Fengna Chu;Jie Zhu. Stem cells therapy in neurodegenerative and neuroimmune diseases: Current status of treatments and future prospects.. Pharmacological research(IF=10.5). 2025. PMID:40976462. DOI: 10.1016/j.phrs.2025.107960.
  • [37] Annalisa Bruno;Cristina Milillo;Federico Anaclerio;Carlotta Buccolini;Anastasia Dell'Elice;Ilaria Angilletta;Marco Gatta;Patrizia Ballerini;Ivana Antonucci. Perinatal Tissue-Derived Stem Cells: An Emerging Therapeutic Strategy for Challenging Neurodegenerative Diseases.. International journal of molecular sciences(IF=4.9). 2024. PMID:38256050. DOI: 10.3390/ijms25020976.
  • [38] Lamya S Shihabuddin;Isabelle Aubert. Stem cell transplantation for neurometabolic and neurodegenerative diseases.. Neuropharmacology(IF=4.6). 2010. PMID:20036262. DOI: 10.1016/j.neuropharm.2009.12.015.
  • [39] Yu Li;Ping-Ping Shen;Bin Wang. Induced pluripotent stem cell technology for spinal cord injury: a promising alternative therapy.. Neural regeneration research(IF=6.7). 2021. PMID:33433463. DOI: 10.4103/1673-5374.303013.
  • [40] Narihito Nagoshi;Osahiko Tsuji;Masaya Nakamura;Hideyuki Okano. Cell therapy for spinal cord injury using induced pluripotent stem cells.. Regenerative therapy(IF=3.5). 2019. PMID:31245451. DOI: 10.1016/j.reth.2019.05.006.
  • [41] Rishi D S Nandoe Tewarie;Rishi D S Nandoe;Andres Hurtado;Allan D O Levi;J Andre Grotenhuis;Andre Grotenhuis;Martin Oudega. Bone marrow stromal cells for repair of the spinal cord: towards clinical application.. Cell transplantation(IF=3.2). 2006. PMID:17176609. DOI: 10.3727/000000006783981602.
  • [42] Fanie Barnabé-Heider;Jonas Frisén. Stem cells for spinal cord repair.. Cell stem cell(IF=20.4). 2008. PMID:18593555. DOI: 10.1016/j.stem.2008.06.011.
  • [43] V Veneruso;F Rossi;A Villella;A Bena;G Forloni;P Veglianese. Stem cell paracrine effect and delivery strategies for spinal cord injury regeneration.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2019. PMID:30851286. DOI: 10.1016/j.jconrel.2019.02.038.
  • [44] Lapo Bonosi;Manikon Poullay Silven;Antonio Alessandro Biancardino;Andrea Sciortino;Giuseppe Roberto Giammalva;Alba Scerrati;Carmelo Lucio Sturiale;Alessio Albanese;Silvana Tumbiolo;Massimiliano Visocchi;Domenico Gerardo Iacopino;Rosario Maugeri. Stem Cell Strategies in Promoting Neuronal Regeneration after Spinal Cord Injury: A Systematic Review.. International journal of molecular sciences(IF=4.9). 2022. PMID:36361786. DOI: 10.3390/ijms232112996.
  • [45] Virginie Neirinckx;Dorothée Cantinieaux;Cécile Coste;Bernard Rogister;Rachelle Franzen;Sabine Wislet-Gendebien. Concise review: Spinal cord injuries: how could adult mesenchymal and neural crest stem cells take up the challenge?. Stem cells (Dayton, Ohio)(IF=3.6). 2014. PMID:24155224. DOI: 10.1002/stem.1579.
  • [46] Iwan Jones;Liudmila N Novikova;Mikael Wiberg;Leif Carlsson;Lev N Novikov. Human Embryonic Stem Cell-derived Neural Crest Cells Promote Sprouting and Motor Recovery Following Spinal Cord Injury in Adult Rats.. Cell transplantation(IF=3.2). 2021. PMID:33522309. DOI: 10.1177/0963689720988245.
  • [47] Jiahui Yong;Jing Tao;Kaiyang Wang;Xia Li;Yining Yang. Post-myocardial Infarction Cardiac Remodeling: Multidimensional Mechanisms and Clinical Prospects of Stem Cell Therapy.. Stem cell reviews and reports(IF=4.2). 2025. PMID:40323498. DOI: 10.1007/s12015-025-10888-7.
  • [48] Seyed Mostafa Parizadeh;Reza Jafarzadeh-Esfehani;Maryam Ghandehari;Mohammad Reza Parizadeh;Gordon A Ferns;Amir Avan;Seyed Mahdi Hassanian. Stem cell therapy: A novel approach for myocardial infarction.. Journal of cellular physiology(IF=4.0). 2019. PMID:30811054. DOI: 10.1002/jcp.28381.
  • [49] Nicholas T Le;Matthew W Dunleavy;William Zhou;Sumrithbir S Bhatia;Rebecca D Kumar;Suyin T Woo;Gonzalo Ramirez-Pulido;Kaushik S Ramakrishnan;Ahmed H El-Hashash. Stem Cell Therapy for Myocardial Infarction Recovery: Advances, Challenges, and Future Directions.. Biomedicines(IF=3.9). 2025. PMID:40427036. DOI: 10.3390/biomedicines13051209.
  • [50] Nandini Nair;Enrique Gongora. Stem cell therapy in heart failure: Where do we stand today?. Biochimica et biophysica acta. Molecular basis of disease(IF=4.2). 2020. PMID:31199998. DOI: 10.1016/j.bbadis.2019.06.003.
  • [51] Mathieu Rheault-Henry;Ian White;Diya Grover;Rony Atoui. Stem cell therapy for heart failure: Medical breakthrough, or dead end?. World journal of stem cells(IF=3.6). 2021. PMID:33959217. DOI: 10.4252/wjsc.v13.i4.236.
  • [52] Reza Rikhtegar;Masoud Pezeshkian;Sanam Dolati;Naser Safaie;Abbas Afrasiabi Rad;Mahdi Mahdipour;Mohammad Nouri;Ahmad Reza Jodati;Mehdi Yousefi. Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs, and skeletal myoblasts.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2019. PMID:30396088. DOI: 10.1016/j.biopha.2018.10.065.
  • [53] Ren Mingliang;Zhang Bo;Wang Zhengguo. Stem cells for cardiac repair: status, mechanisms, and new strategies.. Stem cells international(IF=3.3). 2011. PMID:21776280. DOI: 10.4061/2011/310928.
  • [54] Simon Maltais;Steven J Joggerst;Antonis Hatzopoulos;Thomas G DiSalvo;David Zhao;Hak-Joon Sung;Xintong Wang;John G Byrne;Allen J Naftilan. Stem cell therapy for chronic heart failure: an updated appraisal.. Expert opinion on biological therapy(IF=4.0). 2013. PMID:23289619. DOI: 10.1517/14712598.2013.749852.
  • [55] Shabnur Mahmud;Safaet Alam;Nazim Uddin Emon;Umme Habiba Boby; Kamruzzaman;Firoj Ahmed;A S M Monjur-Al-Hossain;Afroza Tahamina;Sajib Rudra;Marzina Ajrin. Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022.. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society(IF=3.4). 2022. PMID:36249945. DOI: 10.1016/j.jsps.2022.06.017.
  • [56] Shuangpeng Jiang;Guangzhao Tian;Xu Li;Zhen Yang;Fuxin Wang;Zhuang Tian;Bo Huang;Fu Wei;Kangkang Zha;Zhiqiang Sun;Xiang Sui;Shuyun Liu;Weimin Guo;Quanyi Guo. Research Progress on Stem Cell Therapies for Articular Cartilage Regeneration.. Stem cells international(IF=3.3). 2021. PMID:33628274. DOI: 10.1155/2021/8882505.
  • [57] Hyun Jae Lee;Rajib Hossain;Chang-Heon Baek;Choong Jae Lee;Sun-Chul Hwang. Intra-Articular Injection of Stem Cells for the Regeneration of Knee Joint Cartilage: a Therapeutic Option for Knee Osteoarthritis - a Narrative Review.. Biomolecules & therapeutics(IF=3.2). 2025. PMID:39632656. DOI: 10.4062/biomolther.2024.139.
  • [58] Yisi Liu;Meng Wang;Yixuan Luo;Qianyi Liang;Yin Yu;Fei Chen;Jun Yao. Enhancing Stem Cell Therapy for Cartilage Repair in Osteoarthritis-A Hydrogel Focused Approach.. Gels (Basel, Switzerland)(IF=5.3). 2021. PMID:34940323. DOI: 10.3390/gels7040263.
  • [59] Seong Hwan Kim;Yong-Beom Park. Editorial Commentary: Stem Cell Treatment in Knee Osteoarthritis: What for? Pain Management or Cartilage Regeneration?. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association(IF=5.4). 2021. PMID:33384092. DOI: 10.1016/j.arthro.2020.11.017.
  • [60] G-I Im. Clinical use of stem cells in orthopaedics. European cells & materials(IF=3.1). 2017. PMID:28266690. DOI: 10.22203/eCM.v033a14.
  • [61] Bo Cong;Feng-Hua Zhang;Hai-Guang Zhang. Stem cell-based cartilage regeneration: Biological strategies, engineering innovations, and clinical translation.. World journal of stem cells(IF=3.6). 2025. PMID:41025101. DOI: 10.4252/wjsc.v17.i9.108523.
  • [62] Vladislav Volarevic;Bojana Simovic Markovic;Marina Gazdic;Ana Volarevic;Nemanja Jovicic;Nebojsa Arsenijevic;Lyle Armstrong;Valentin Djonov;Majlinda Lako;Miodrag Stojkovic. Ethical and Safety Issues of Stem Cell-Based Therapy.. International journal of medical sciences(IF=3.2). 2018. PMID:29333086. DOI: 10.7150/ijms.21666.
  • [63] Nicolas S Piuzzi;Ahmed Emara;Jorge Chahla;Bert R Mandelbaum. Ethical and Practical Considerations for Integrating Cellular ("Stem Cell") Therapy into Clinical Practice.. Current reviews in musculoskeletal medicine(IF=3.9). 2020. PMID:32468421. DOI: 10.1007/s12178-020-09647-7.
  • [64] Douglas Sipp. The unregulated commercialization of stem cell treatments: a global perspective.. Frontiers of medicine(IF=3.5). 2011. PMID:21964637. DOI: 10.1007/s11684-011-0150-x.
  • [65] Hany E Marei. Stem cell therapy: a revolutionary cure or a pandora's box.. Stem cell research & therapy(IF=7.3). 2025. PMID:40405306. DOI: 10.1186/s13287-025-04334-1.
  • [66] Carlo Petrini. Bioethics of Clinical Applications of Stem Cells.. International journal of molecular sciences(IF=4.9). 2017. PMID:28417921. DOI: 10.3390/ijms18040814.
  • [67] Ioannis Alexandros Charitos;Andrea Ballini;Stefania Cantore;Mariarosaria Boccellino;Marina Di Domenico;Elisa Borsani;Riccardo Nocini;Michele Di Cosola;Luigi Santacroce;Lucrezia Bottalico. Stem Cells: A Historical Review about Biological, Religious, and Ethical Issues.. Stem cells international(IF=3.3). 2021. PMID:34012469. DOI: 10.1155/2021/9978837.
  • [68] H Ozturk Turkmen;B Arda. Ethical and legal aspects of stem cell practices in Turkey: where are we?. Journal of medical ethics(IF=3.4). 2008. PMID:19043103. DOI: 10.1136/jme.2007.022806.
  • [69] Jeremy Sugarman;Roger A Barker;Ian Kerridge;Tamra Lysaght;Graziella Pellegrini;Douglas Sipp;Claire Tanner. Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.. Stem cell reports(IF=5.1). 2018. PMID:30428384. DOI: 10.1016/j.stemcr.2018.10.020.
  • [70] Pravin Shende;Hunny Gupta;R S Gaud. Cytotherapy using stromal cells: Current and advance multi-treatment approaches.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2018. PMID:29080456. DOI: 10.1016/j.biopha.2017.10.127.
  • [71] Akbar Hasanzadeh;Arefeh Ebadati;Lida Dastanpour;Amir R Aref;Parham Sahandi Zangabad;Alireza Kalbasi;Xiaofeng Dai;Geeta Mehta;Amir Ghasemi;Yousef Fatahi;Suhasini Joshi;Michael R Hamblin;Mahdi Karimi. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.. ACS pharmacology & translational science(IF=3.7). 2023. PMID:38093832. DOI: 10.1021/acsptsci.3c00102.
  • [72] Mitsushige Murata;Shugo Tohyama;Keiichi Fukuda. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.. Pharmacology & therapeutics(IF=12.5). 2010. PMID:20156482. DOI: 10.1016/j.pharmthera.2010.01.010.
  • [73] Amanda L Facklam;Lisa R Volpatti;Daniel G Anderson. Biomaterials for Personalized Cell Therapy.. Advanced materials (Deerfield Beach, Fla.)(IF=26.8). 2020. PMID:31495970. DOI: 10.1002/adma.201902005.
  • [74] K K Jain. Role of biological therapies in the development of personalized medicine.. Expert opinion on biological therapy(IF=4.0). 2012. PMID:22107592. DOI: 10.1517/14712598.2012.641010.
  • [75] Chinedu Cletus Ude;Azizi Miskon;Ruszymah Bt Hj Idrus;Muhamad Bin Abu Bakar. Application of stem cells in tissue engineering for defense medicine.. Military Medical Research(IF=22.9). 2018. PMID:29502528. DOI: 10.1186/s40779-018-0154-9.
  • [76] Shaima Maliha Riha;Manira Maarof;Mh Busra Fauzi. Synergistic Effect of Biomaterial and Stem Cell for Skin Tissue Engineering in Cutaneous Wound Healing: A Concise Review.. Polymers(IF=4.9). 2021. PMID:34065898. DOI: 10.3390/polym13101546.
  • [77] Souzan Salemi;Jenny A Prange;Valentin Baumgartner;Deana Mohr-Haralampieva;Daniel Eberli. Adult stem cell sources for skeletal and smooth muscle tissue engineering.. Stem cell research & therapy(IF=7.3). 2022. PMID:35410452. DOI: 10.1186/s13287-022-02835-x.
  • [78] Guiting Liu;Yuan Zhou;Xianlong Zhang;Shaoyun Guo. Advances in hydrogels for stem cell therapy: regulation mechanisms and tissue engineering applications.. Journal of materials chemistry. B(IF=5.7). 2022. PMID:35819152. DOI: 10.1039/d2tb01044e.
  • [79] Anthony Atala. Tissue engineering of reproductive tissues and organs.. Fertility and sterility(IF=7.0). 2012. PMID:22748231. DOI: 10.1016/j.fertnstert.2012.05.038.
  • [80] Faramarz Edalat;Hojae Bae;Sam Manoucheri;Jae Min Cha;Ali Khademhosseini. Engineering approaches toward deconstructing and controlling the stem cell environment.. Annals of biomedical engineering(IF=5.4). 2012. PMID:22101755. DOI: 10.1007/s10439-011-0452-9.
  • [81] Malgorzata Maj;Anna Kokocha;Anna Bajek;Tomasz Drewa. The interplay between adipose-derived stem cells and bladder cancer cells.. Scientific reports(IF=3.9). 2018. PMID:30310111. DOI: 10.1038/s41598-018-33397-9.
  • [82] Yuanhao Xie;Chenqi Tang;Zizhan Huang;Sicheng Zhou;Yuwei Yang;Zi Yin;Boon Chin Heng;Weishan Chen;Xiao Chen;Weiliang Shen. Extracellular Matrix Remodeling in Stem Cell Culture: A Potential Target for Regulating Stem Cell Function.. Tissue engineering. Part B, Reviews(IF=4.6). 2022. PMID:34082581. DOI: 10.1089/ten.TEB.2021.0066.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Stem Cell Therapy · Regenerative Medicine · Ethical Issues

© 2025 MaltSci